Floatz Rating
CC40/100
Confidence
Indicative
Sponsor
Seoul National University Bundang Hospital
Modality
antibody_drug_conjugate
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05525858CT.gov KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | — | Recruiting | — | — | — |
NCT05081609CT.gov A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | — | Active Not Recruiting | — | — | — |
NCT05593094CT.gov A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02318901CT.gov Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab Emtansine (this asset) | Seoul National University Bundang Hospital | P1/2 | CC · 40 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | P4 | BB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Fluorouracilum | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | InSilico Medicine Hong Kong Limited | P4 | BB |
| Trametinib | Cancer Research UK | P2/3 | BB |
+42 more in the Cancer cohort
Other indications for Trastuzumab Emtansine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P3 | BB · 67 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 66 |
| Breast Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab Emtansine in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-emtansine-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →